SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is trending as discussions revolve around its potential role in the Real World Asset (RWA) space, with some community members envisioning tokenized assets like houses being used as collateral on its blockchain. However, concerns persist regarding the project's revenue and financial sustainability, with some users pointing to its cashflow and governance as potential issues. Overall, there is much debate around the future of the project and its place in the evolving crypto landscape.

“Hmmm” is a community meme token on the Solana network, launched on July 22, 2024, through Pumpfun. It’s a derivative of Pepe the Frog but has evolved into its own distinct meme with a unique identity. The token embraces the humor and intrigue of internet culture, playing on the idea of curiosity and speculation. “Hmmm” captures a playful approach to the world of meme tokens, designed to engage a community driven by fun and the whimsical side of crypto. Hmmm, maybe this’ll send.

hmmm

The crypto token HMMM is trending as the community highlights its potential and notes its integration with Phantom Wallet. Social media buzz suggests growing interest and positive sentiment around HMMM, with many anticipating a potential breakout. Community members are using terms like "moon," "rocket," and "early entries" to describe their expectations for the token's performance.

$RARI is an ERC-20 token that controls the RARI Foundation treasury and governs the Rarible protocol and RARI Chain. The token was issued in 2020 with a max. supply of 25 million $RARI.

Rarible

Rarible is trending as traders discuss its low market cap and potential for significant upward movement, with some eyeing a potential Binance listing as a major catalyst. Community members are actively speculating on entry points and anticipating a breakout, citing its limited supply and previous highs as reasons for optimism. Recent integration with Aleph Zero is also being highlighted.

Exxon Mobil Corp. engages in the exploration, development, and distribution of oil, gas, and petroleum products. It operates through the following segments: Upstream, Energy Products, Chemical Products, and Specialty Products. The Upstream segment organizes the exploration of crude oil and natural gas. The Energy Products segment includes fuels, aromatics, and catalyst and licensing. The Chemical Products segment offers petrochemicals. The Specialty Products segment provides finished lubricants, basestocks and waxes, synthetics, and elastomers and resins. The company was founded by John D. Rockefeller in 1882 and is headquartered in Spring, TX.

Exxon Mobil Corp.

Exxon Mobil Corp

Energy prices are in focus as XOM trends, with community members discussing potential breakouts and resistance levels. Bullish sentiment is fueled by news of production milestones in Guyana and a new deepwater deal, while some analysts are focused on XOM's cash flow and valuation. Discussions also include potential impacts from geopolitical events and the possibility of XOM returning to Russia.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as traders discuss its potential in the play-to-earn and virtual world sectors, focusing on its technology that bridges blockchain with gaming. Community members are weighing in on entry points and whether it's still early to invest, while also noting its recent listing on Robinhood and its ecosystem of AI agents. The conversation highlights the potential for significant growth, although some caution against pump-and-dump schemes.

Definitive is an onchain trading platform democratizing advanced trading tools for the masses. Trade any token on any chain with advanced trade order types including Market, Limit Buy/Sell, Stop Loss and TWAP orders.  Route your trade instantly across 100+ DEXs and liquidity pools to get the best prices on every trade. Definitive is built by former Coinbase Institutional trading alumni and active DeFi experts.

Definitive

EDGE is trending as community members discuss its recent price movements and potential for further gains, particularly in relation to BTC's performance. Some investors are highlighting the token's fundamentals, potential catalysts, and possible links to Coinbase, while others are closely watching for breakout opportunities and key resistance levels. The community is also weighing in on its trading platform and potential Binance listing.

NXP Semiconductors NV is a holding company which engages in the provision of semiconductor solutions. It operates through the following geographical segments: China, Netherlands, United States, Singapore, Germany, Japan, South Korea, Malaysia, and Other Countries. The company was founded on August 2, 2006, and is headquartered in Eindhoven, the Netherlands.

NXP Semiconductors NV

NXPI is trending amidst discussions around potential earnings beats and strong automotive demand offsetting weakness in other sectors. The community is actively debating whether the stock is building a solid foundation for an explosive move, while also considering the impact of competitor activities and unusual options activity. Updates from SEMICON West 2025, focusing on AI demand and supply chain resilience, are adding to the conversation.

AvePoint, Inc. operates as a digital collaboration innovator, which provides data management services. It develops, markets, and sells its suite of software solutions and services in North America, Europe, Australia, and Asia. The company was founded on July 24, 2001 and is headquartered in Jersey City, NJ.

AvePoint Inc - Ordinary Shares - Class A

AvePoint is trending due to Morgan Stanley initiating coverage as "overweight," calling it an "underappreciated" data security play, though some investors remain skeptical after years of stagnant growth since its SPAC days. Community discussions revolve around the company's potential, insider selling activity, and a recent settlement with investors over claims of a misleading de-SPAC merger in 2021. Some investors are optimistic about upcoming catalysts like the November quarterly report, while others express frustration with the stock's historical performance.

Chevron Corp. engages in the provision of administrative, financial management, and technology support for energy and chemical operations. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevron is trending as investors monitor rising geopolitical tensions and their potential impact on oil prices, particularly after reports of strikes in the Middle East. Community members are closely watching technical indicators and potential gap fills, while analysts weigh in on the company's long-term strategies, including expansion projects and cost-cutting initiatives. Some traders are seeing opportunity amidst volatility with the potential for call options to print.

SSgA Active Trust - The Energy Select Sector SPDR Fund

Energy Select Sector SPDR Fund

The Energy Select Sector SPDR Fund ($XLE) is trending due to rising geopolitical tensions, particularly following reported U.S. strikes on Iran and concerns about potential disruptions in the Strait of Hormuz, sparking community discussion around supply implications and price targets. Bullish sentiment is fueled by anticipation of higher oil prices, while bearish perspectives cite potential oversupply and historical patterns after OPEC meetings. Community members are actively discussing trading strategies, potential entry/exit points, and the impact of various factors, including U.S. policy and global demand, on the energy sector's performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Are Medical Stocks Lagging  ANI Pharmaceuticals (ANIP) This Year?

Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.

Celldex Therapeutics shares slipped in after-hours trading&nbsp;on&nbsp;Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis (EoE).The stock closed down 1.9% at $24.02 on Tuesday and slid another 14.2% to $20.62 in after-hours trading following its Phase 2 EoE update.The decision to pull the plug on the&nbsp;EoE candidate came after&nbsp;the Phase 2 trial hit its primary goal by reducing mast cells in the esophagus, but the depletion failed to bring meaningful improvements for patients.No differences were observed between barzolvolimab and placebo in dysphagia symptom scores, endoscopic assessment of inflammation and fibrosis, or histological reduction in eosinophil infiltration.&nbsp;Celldex said the results provide direct evidence that mast cells are not a primary driver of the disease.The study confirmed barzolvolimab’s favorable safety and tolerability profile at the dosing regimen that was tested, consistent with prior studies where dosing was less frequent.&nbsp;“While we are disappointed in the clinical outcome in EoE, we are proud of our role in advancing the science for patients who need more effective treatment options,” said Chief Executive Officer Anthony Marucci.Marucci added that Celldex remains committed to barzolvolimab’s broader pipeline, with enrollment ongoing in four studies: two Phase 3 trials in chronic spontaneous urticaria and two Phase 2 trials in atopic dermatitis and prurigo nodularis.&nbsp;The company is also finalizing plans to initiate a Phase 3 program in inducible urticaria, covering cold urticaria and symptomatic dermographism.On Stocktwits, retail sentiment for Celldex was ‘bullish’ amid ‘high’ message volume.One user focused on Celldex’s pivot toward chronic spontaneous urticaria (CSU), saying investors are primarily betting on the Phase 3 program after strong Phase 2 data, which they described as better than the current standard of care.&nbsp;They noted that CSU represents a much larger commercial opportunity, with market leader Xolair bringing in more than $4 billion in revenue in 2024.<stembedurl>https://stocktwits.com/TheGunnerAB/message/625855252</stembedurl>Another user suggested the pullback could be a buying opportunity, calling it a good time to add to positions in Celldex.<stembedurl>https://stocktwits.com/StockHunter75/message/625842884</stembedurl><a href="https://stocktwits.com/symbol/CLDX">Celldex’s stock</a> has declined 5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Celldex Therapeutics (CLDX) shares slipped in after-hours trading on Tuesday after the biotech said it will stop developing barzolvolimab for eosinophilic esophagitis. (Photo credit: Getty Images)

Why Are Celldex Shares Tumbling After Hours?

The biotech firm said it would halt development of barzolvolimab in eosinophilic esophagitis following Phase 2 results that met the trial’s primary goal but failed to show clinical benefit. 

Equity

Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates

Celldex (CLDX) delivered earnings and revenue surprises of +1.16% and -56.18%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

scPharmaceuticals (SCPH) Soars 8.8%: Is Further Upside Left in the Stock?

scPharmaceuticals (SCPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Retail investor chatter around Celldex Therapeutics spiked on Sunday following new Phase 2 data showing barzolvolimab provided “profound long-term” relief from angioedema in patients with chronic spontaneous urticaria (CSU).Celldex shares closed 4.5% higher at $21.26 on Friday.The company presented updated 52-week results at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Congress in Glasgow, showing that 77% of patients on barzolvolimab were angioedema-free at Week 52.&nbsp;The antibody therapy also showed up to 87% of patients reported “clinically meaningful” improvements in angioedema activity scores (AAS7).Barzolvolimab targets KIT, a receptor tyrosine kinase involved in mast cell regulation.&nbsp;In CSU, mast cells drive persistent inflammation and swelling even after standard antihistamine therapy fails.Patients with severe CSU and angioedema frequently endure disfigurement and debilitating pain, said Diane C. Young, MD, Chief Medical Officer at Celldex.&nbsp;Additional data showed an 86% mean reduction in angioedema activity in the 150 mg group and 82% in the 300 mg every-8-weeks group.&nbsp;Patients remained angioedema-free for 72% of the year-long treatment period.Retail sentiment on platforms such as Stocktwits and Reddit turned sharply bullish over the weekend, with several users highlighting the durability of symptom control and potential differentiation from existing CSU treatments like Novartis’ Xolair.The 208-patient Phase 2 trial had previously met all primary and secondary endpoints at 12 weeks.&nbsp;A global Phase 3 program is underway, targeting antihistamine-refractory CSU patients, including those previously treated with biologics.On Stocktwits, retail sentiment was ‘bearish’ amid ‘extremely high’ message volume.Celldex stock has declined 17.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Generic capsules, 25 July 2004. AFR Picture by LOUIE DOUVIS (Photo by Fairfax Media via Getty Images)

Celldex Study Finds Most Patients Symptom-Free From Angioedema After One Year; Retail Bulls Stay Guarded

Celldex’s candidate targets KIT, a mast cell receptor tied to CSU inflammation, and had earlier met all key endpoints at 12 weeks.

Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue?

Beyond The Numbers: 11 Analysts Discuss Celldex Therapeutics Stock

Latest Ratings for CLDX
 DateFirmActionFromTo Sep 2021JefferiesInitiates Coverage OnBuy Sep 2021HC Wainwright & Co.MaintainsBuy Sep 2021SVB LeerinkInitiates Coverage OnOutperform
 View More...

Analyst Expectations For Celldex Therapeutics's Future

A Closer Look at 10 Analyst Recommendations For Celldex Therapeutics

7 Analysts Have This To Say About Celldex Therapeutics

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$24.95
Beta	1.14
Avg. Volume	1.33M
PE Ratio	-8.88

52-Week High	$29.38
52-Week Low	$14.40
Market Capitalization	$1.77B
EPS (Annual)	-$2.45
Price to Book	2.71
Revenue Per Employee	$37,741.93
Enterprise Value/EBITDA	N/A

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CLDX News

CLDXCelldex Therapeutics Inc.